Email this article Efficacy of camrelizumab in combination with capecitabine and stereotactic radiation therapy in oligoprogressing squamous cell carcinomas
- Authors: Vakhabova Y.V.1, Nidal S.1, Koposov P.V.1, Moskalets E.R.1, Loiko I.E.1
-
Affiliations:
- European Medical Center
- Issue: Vol 16, No 1 (2026)
- Pages: 84-88
- Section: CLINICAL CASE
- Published: 09.06.2026
- URL: https://ogsh.abvpress.ru/jour/article/view/1159
- DOI: https://doi.org/10.17650/2222-1468-2026-16-1-84-88
- ID: 1159
Cite item
Open Access
Access granted
Subscription or Fee Access
Abstract
Camrelizumab is a monoclonal antibody against programmed cell death protein 1 (PD-1) which demonstrated clinical efficacy in esophageal squamous cell carcinoma including in combination with 1st line chemotherapy cases of advanced disease. The article describes a clinical case of administration of camrelizumab + capecitabin in combination with local ablative intervention in the form of stereotactic radiation therapy for treatment of oligoprogressing esophageal squamous cell carcinoma. This observation shows clinical advisability of continuing immunomodulating therapy in cases of limited tumor progression with simultaneous local control of the lesions with the highest biological activity.
About the authors
Y. V. Vakhabova
European Medical Center
Author for correspondence.
Email: yuvahabova@emcmos.ru
ORCID iD: 0000-0002-2209-4410
Russian Federation, 35 Shchepkina St., Moscow, 129090
S. Nidal
European Medical Center
Email: yuvahabova@emcmos.ru
ORCID iD: 0000-0003-2630-4961
Russian Federation, 35 Shchepkina St., Moscow, 129090
P. V. Koposov
European Medical Center
Email: yuvahabova@emcmos.ru
ORCID iD: 0000-0001-8789-9271
Russian Federation, 35 Shchepkina St., Moscow, 129090
E. R. Moskalets
European Medical Center
Email: yuvahabova@emcmos.ru
ORCID iD: 0000-0002-0164-2422
Russian Federation, 35 Shchepkina St., Moscow, 129090
I. E. Loiko
European Medical Center
Email: yuvahabova@emcmos.ru
ORCID iD: 0000-0002-6909-8558
Russian Federation, 35 Shchepkina St., Moscow, 129090
References
- Luo H., Lu J., Bai Y. et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA 2021;326(10):916–25. doi: 10.1001/jama.2021.12836
- He M., Wang Z., Lu J. et al. Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st trial. Med 2024;5(9):1137–49.e3. doi: 10.1016/j.medj.2024.05.008
- Имянитов Е.Н., Суладзе С.А., Пешкова Ю.О. и др. Камрелизумаб – первый поливалентный pD-1-ингибитор в Российской Федерации. Опухоли головы и шеи 2025;15(4):41–51. doi: 10.17650/2222-1468-2025-15-4-41-51 Imyanitov E.N., Suladze S.A., Peshkova I.O. et al. Camrelizumab exhibits dual specificity implications for antitumor immunity. Opukholi golovy i shei = Head and Neck Tumors 2025;15(4):41–51. (In Russ.). doi: 10.17650/2222-1468-2025-15-4-41-51
- Zhou R.Q., Luo J., Li L.J. et al. Neoadjuvant camrelizumab plus chemotherapy in locally advanced oesophageal squamous cell carcinoma: a retrospective cohort study. BMC Surg 2023;23:114. doi: 10.1186/s12893-023-02023-5
- Qin J., Fang W., Li Y. et al. Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial. Nat Med 2024;30(9):2549–57. doi: 10.1038/s41591-024-03064-w
- Chen F., Qiu L., Mu Y. et al. Neoadjuvant chemoradiotherapy with camrelizumab in patients with locally advanced esophageal squamous cell carcinoma. Front Surg 2022;9:893372. doi: 10.3389/fsurg.2022.893372
Supplementary files
